IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

ProSense® shows high 12-month response rates, but commercial traction remains unproven.

What the company is saying

IceCure Medical Ltd. is highlighting the clinical momentum of its ProSense® breast cancer cryoablation system, focusing on its prominent role at the EUSOBI Annual Scientific Meeting 2026 in the Netherlands. The company emphasizes 12-month clinical data showing a 97.5% objective response rate among 40 patients treated with cryoablation plus endocrine therapy, and a 91.7% rate among 24 patients treated with cryoablation alone. IceCure frames these results as evidence of strong physician engagement and growing clinical interest in Europe, reinforced by ProSense® being featured in two key scientific sessions and two workshops, each drawing nearly 70 participants. The announcement also stresses that ProSense® is the first and only FDA-cleared device for local treatment of breast cancer in patients aged 70 and older with low-risk tumors ≤1.5 cm treated with adjuvant endocrine therapy. CEO Eyal Shamir describes the response at EUSOBI as 'tremendous' and points to the inclusion in scientific posters and presentations as signs of expanding momentum. The tone is confident and promotional, with repeated references to enthusiasm, engagement, and the device’s expanding role, but without mention of financial or commercial outcomes.

What the data suggests

The disclosed numbers show that ProSense® achieved a 97.5% objective response rate at 12 months among 40 patients treated with cryoablation plus endocrine therapy, and a 91.7% rate among 24 patients treated with cryoablation alone. These figures suggest strong short-term clinical efficacy in a limited patient population. The workshops at EUSOBI attracted nearly 70 participants each, indicating meaningful physician interest and engagement within the European breast imaging community. The FDA clearance is limited to patients aged 70 and older with biologically low-risk tumors ≤1.5 cm who are treated with adjuvant endocrine therapy, which defines a narrow initial market. No revenue, sales, or commercial adoption metrics are disclosed, so there is no evidence of market penetration or financial impact. The announcement is comprehensive in reporting clinical and event participation data but omits all commercial metrics, making it impossible to assess the business trajectory or adoption beyond the clinical research setting.

Analysis

The announcement is upbeat, emphasizing strong clinical engagement and promising 12-month response rates for ProSense® cryoablation in breast cancer. The majority of claims are realised and supported by specific clinical data (objective response rates, patient numbers, workshop participation), and the FDA clearance for a defined indication is a concrete regulatory milestone. However, the release also contains forward-looking statements about potential increased adoption and commercial expansion, which are not yet realised and lack supporting sales or financial data. There is no disclosure of revenue, profitability, or commercial uptake, so the investment case rests on clinical promise and regulatory status rather than measurable financial progress. The language around 'growing clinical interest' and 'strong response' at the conference is somewhat promotional but not extreme. No large capital outlay or long-dated, uncertain returns are discussed, and the execution timeline for commercial benefits is not specified.

Risk flags

• ●The absence of any disclosed commercial sales, revenue, or adoption metrics means there is no evidence that strong clinical results are translating into market traction or financial returns. This gap raises uncertainty about the pace and scale of commercialisation.
• ●The FDA clearance for ProSense® is limited to a narrow patient segment—those aged 70 and older with low-risk tumors ≤1.5 cm and on adjuvant endocrine therapy—which may restrict the addressable market and slow broader adoption.
• ●Reliance on conference participation and physician enthusiasm as leading indicators of commercial momentum is risky, as such engagement does not guarantee purchasing decisions or reimbursement support.

Bottom line

IceCure Medical's latest update demonstrates that ProSense® delivers high 12-month objective response rates in small patient cohorts and is generating significant clinical interest among European breast imaging specialists. The company’s narrative is built on strong clinical engagement and regulatory milestones, but it provides no evidence of commercial sales, revenue, or broader market adoption. The FDA clearance applies only to a narrowly defined patient group, which may limit near-term commercial impact. For investors, the key takeaway is that while clinical results are promising, the lack of financial or adoption data means the investment case remains speculative. To shift this assessment, IceCure would need to disclose concrete sales figures, revenue growth, or evidence of broader market uptake. Until then, the story is one of clinical promise with unproven commercial results.

Announcement summary

(NASDAQ:ICCM) IceCure Medical Ltd. announced that its ProSense® breast cancer cryoablation system was featured in multiple scientific presentations, research posters, and physician workshops at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands. The event included the presentation of 12-month clinical data showing an objective response rate of 97.5% among 40 patients treated with cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone. ProSense® was highlighted in two key scientific sessions, reflecting growing clinical interest in breast cancer cryoablation in Europe. Dr. Lucía Graña-López (Lugo, Spain) presented on the clinical potential of cryoablation in the session "From Target to Treatment: Breast Interventions." Dr. Francesca Pugliese (Florence, Italy) shared findings on local tumor control in elderly breast cancer patients ineligible for surgery, comparing cryoablation alone and in combination with hormonal therapy. IceCure Medical hosted two clinical workshops led by Dr. Lucía Graña-López and Dr. Federica Di Naro (Florence, Italy), titled "From Freeze to Future: Cryoablation as a New Frontier in De-Escalated Breast Cancer Care" and "Reading the Freeze: Practical Imaging Interpretation After Breast Cancer Cryoablation," each attracting nearly 70 participants. Two scientific posters by ProSense® users were presented: one by Dr. Georgiana-Cristiana Camen (Romania) on single-center efficacy and safety outcomes for breast lesion cryoablation, and another by Dr. Francesca Pugliese on the predictive value of negative contrast enhancement mammography after breast cryoablation. EUSOBI is a leading European organization for breast imaging and education, and its annual meeting serves as a platform for sharing clinical knowledge and research advances. Eyal Shamir, Chief Executive Officer of IceCure Medical, stated that the company was thrilled by the enthusiasm and engagement ProSense® generated at EUSOBI, noting the strong response to live demonstrations, scientific sessions, workshops, and the presentation of encouraging 12-month clinical results. The ProSense® system is marketed and sold worldwide for approved indications, including in the United States, Europe, and Asia. ProSense® cryoablation is the first and only medical device cleared by the FDA for local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including those not eligible for surgery.

Disagree with this article?